AAgilent Technologies

8 paragraphs in Risk Factors of the 10-K filed Dec 22, 2025 with nothing like them in the 10-K filed Dec 20, 2024. Quoted exactly. Paragraphs that were only edited are under 10-K change.

Compared with the Risk Factors in the latest 10-K of the other 59 Health care companies: a paragraph with at least half its words the same at another company is called similar, and the companies are listed under it. A paragraph most of them have is marked boilerplate. No line means no other company has one like it. This counts text; it does not say how serious a risk is.

Recent and dynamic government rule making and policy changes could increase our costs, affect our markets and customers and impact our results of operations.

The rapid increase in new government regulations, including tariffs and proposed tariffs in the geographies and markets in which we operate, could result in significant costs and require modifications in the way we and our customers conduct business. As we and our customers respond to newly enacted rules and legislation, effects on purchasing behavior and global trade relationships could affect our revenue. Increases in our costs and expenses related to our compliance or mitigation activities and those of our customers and suppliers could have a negative effect on our operating margin. If we are unable to respond to changing regulations in a timely and effective manner, our results of operations could be adversely affected.

In addition, geopolitical instability and evolving trade regulations, including tariffs, sanctions, and export controls, may restrict our ability to ship products globally or source critical components. These developments can increase costs, disrupt supply chains, and require operational adjustments. Failure to comply with these regulations could result in penalties, loss of export privileges, and reputational harm.

Currently, United States federal agencies are operating under a continuing resolution that is set to expire on January 30, 2026. Without appropriation of additional funding to federal agencies, our business operations related to our product sales to customers receiving funding from the U.S. federal government could be impacted. Inadequate funding for government agencies, including from government shut downs, or other disruptions to these agencies’ operations, such as actions to greatly reduce the size of the federal workforce, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions on which the operation of the businesses of certain of our customers and our business may rely, which could negatively impact our business.

Similar paragraph at 1 of 59 other Health care companies: MRNA

Read in the 10-K ↗

Share this quote X LinkedIn Reddit WhatsApp Telegram Copy link Image

The expectations and requirements of regulators and other key stakeholders, including on corporate governance and sustainability-related matters, continue to evolve and diverge, and our ability to meet these expectations and requirements could impact our risk exposure and financial conditions.

Similar paragraph at 1 of 59 other Health care companies: IQV

We are subject to rapidly changing and varied expectations and requirements, including on corporate governance and sustainability issues, from a wide range of stakeholders, such as governmental and self-regulatory organizations, including the Securities and Exchange Commission, U.S. federal and state governments, New York Stock Exchange, and the European Union, as well as our investors, customers and suppliers. In addition, many of our stakeholders have diverging demands, perspectives and preferences, including on topics such as climate change and diversity. We may not be able to meet the diverse expectations and demands of all of our stakeholders, which could result in an adverse impact on our business, financial results, stock price or reputation, and subject us to legal, reputational and operational risks.

Similar paragraph at 1 of 59 other Health care companies: IQV

For example, U.S. federal, state and local governmental authorities, as well as governmental authorities in various jurisdictions, have proposed or implemented and are likely to continue to propose or implement, legislative and regulatory initiatives around corporate governance and environmental and social practices and disclosures. Compliance with such evolving expectations, rules and regulations, including any that may emerge in the future as well as those incorporated in our contractual obligations from our customers, could increase the cost and complexity of operating our business, and could adversely impact us. In addition, various jurisdictions have adopted or proposed laws, regulations and policies that diverge from, or potentially conflict with, those adopted or proposed in other jurisdictions, making compliance more difficult and uncertain. Failure to comply with any law, regulation or policy, including as a result of making good faith interpretations that may differ from those taken by authorities in relevant jurisdictions, could potentially result in legal, reputational and operational risks.

Similar paragraph at 1 of 59 other Health care companies: IQV

Furthermore, any actual or perceived failure to achieve our current and future sustainability goals, including those which result from contractual obligations from our customers, or to act responsibly with respect to such matters or to effectively respond to new or additional sustainability-related legal or regulatory requirements, could result in adverse publicity and adversely affect our business and reputation. There is no assurance that we will be able to successfully achieve any sustainability-related goal or execute on any sustainability-related strategy, or adequately meet stakeholder expectations with respect to such matters. Our ability to deliver on any sustainability-related goal or strategy is subject to numerous risks, many of which are outside of our control. These factors include rapidly shifting regulatory requirements and stakeholder expectations, our ability to recruit and retain a robust workforce, the activities and availability of suppliers and other business partners, cost considerations and the development and availability of cost-effective technologies or resources.

Similar paragraph at 1 of 59 other Health care companies: IQV

Read in the 10-K ↗

Share this quote X LinkedIn Reddit WhatsApp Telegram Copy link Image

New in the latest 10-Q

10 paragraphs in the 10-Q filed Sep 1, 2026 with nothing like them in the 10-Q filed Jun 1, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

In May 2026, the Financial Accounting Standards Board ("FASB") issued new guidance related to environmental credits and environmental credit obligations. The guidance establishes recognition, measurement, presentation, and disclosure requirements for environmental credits and environmental credit obligations. The guidance is effective for our fiscal year 2029, including interim periods within that year, with early adoption permitted. We are currently evaluating the effect of adopting this guidance on our condensed consolidated financial statements.

Read in the 10-Q ↗

The Biocare acquisition was accounted for in accordance with the authoritative accounting guidance for business combinations. The acquired assets and assumed liabilities were recorded at their estimated fair values. We determined the estimated fair values with the assistance of valuations performed by a third-party specialist, discounted cash flow analyses and estimates made by management. We expect to realize revenue synergies, expand the existing sales channels and product development resources, and benefit from the assembled workforce. These factors, among others, contributed to a purchase price in excess of the estimated fair value of Biocare’s net identifiable assets acquired (see summary of net assets below), and, as a result, we have recorded goodwill in connection with this transaction. All goodwill acquired was allocated to the Life Sciences and Diagnostics Markets operating segment and reporting unit as part of the purchase price allocation.

Read in the 10-Q ↗

Our acquisition of Biocare is treated as a stock acquisition and therefore is not deductible for United States federal tax purposes.

Read in the 10-Q ↗

The following table summarizes the allocation of the purchase price to the estimated fair values of the assets acquired and liabilities assumed on the closing date of June 24, 2026 (in millions):

Read in the 10-Q ↗

Purchase Price Cash paid $ 964 Less: Cash acquired (14) Net cash consideration $ 950 Net assets acquired Current assets 27 Property, plant and equipment 8 Goodwill 549 Other intangible assets: Customer relationships 372 Developed technology 145 Trade names 3 Other assets 6 Liabilities assumed (59) Deferred tax liability (101) Total net assets acquired $ 950

Read in the 10-Q ↗

Other identifiable intangible assets consist of customer relationships, developed technology, and trade names. These finite-lived intangible assets have estimated useful lives of 15 years for customer relationships and developed technology and 3 years for trade names, resulting in a weighted-average estimated useful life of approximately 15 years.

Read in the 10-Q ↗

Supplemental pro forma revenue and net income have not been presented because the effects of the acquisition were not material to our condensed consolidated financial statements.

Read in the 10-Q ↗

Gain (loss) on time value of forward contracts recorded in cost of revenue $ 2 $ 2 $ 6 $ 5

Read in the 10-Q ↗

software. These solutions range from standalone automation platforms to integrated workflow solutions with seamless integration to our instrumentation.

Read in the 10-Q ↗

At July 31, 2026, our headcount was approximately 18,200 as compared to 18,000 at July 31, 2025. The increase in headcount is primarily due to our recent acquisition.

Read in the 10-Q ↗

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Sep 1, 2026 against Item 1A of the 10-K filed Dec 22, 2025. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted and underlined). Text on the page, not a score; each links to the filing at sec.gov.